Vigilare Wealth Management Affimed N.V. Transaction History

Vigilare Wealth Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 10, 2023	SELL	$1.1 - $2.45 $9,790 - $21,805	-8,900 Reduced 44.17%	11,250 $0
Q3 2022 Oct 20, 2022	SELL	$1.96 - $3.32 $6,860 - $11,620	-3,500 Reduced 14.8%	20,150 $42,000
Q2 2022 Jul 11, 2022	SELL	$2.27 - $4.86 $104,306 - $223,317	-45,950 Reduced 66.02%	23,650 $66,000
Q1 2022 Apr 06, 2022	SELL	$3.69 - $5.65 $53,043 - $81,218	-14,375 Reduced 17.12%	69,600 $304,000
Q4 2021 Jan 07, 2022	BUY	$5.37 - $7.07 $5,907 - $7,777	1,100 Added 1.33%	83,975 $464,000
Q3 2021 Oct 19, 2021	BUY	$5.54 - $7.51 $94,650 - $128,308	17,085 Added 25.97%	82,875 $512,000
Q2 2021 Jul 16, 2021	BUY	$7.78 - $11.4 $32,987 - $48,336	4,240 Added 6.89%	65,790 $559,000
Q1 2021 Apr 29, 2021	BUY	$5.12 - $8.48 $81,664 - $135,256	15,950 Added 34.98%	61,550 $487,000
Q4 2020 Jan 14, 2021	BUY	$3.16 - $7.03 $24,648 - $54,834	7,800 Added 20.63%	45,600 $265,000
Q3 2020 Oct 15, 2020	BUY	$3.26 - $4.73 $27,742 - $40,252	8,510 Added 29.05%	37,800 $128,000
Q2 2020 Jul 20, 2020	BUY	$1.58 - $4.63 $46,278 - $135,612	29,290 New	29,290 $135,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Vigilare Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Vigilare Wealth Management with notifications on news.